658 results on '"Kirk, Christopher"'
Search Results
152. Assessment of Cytokine-Modulated Proteasome Activity.
153. Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation
154. Discovery and Development of Second-Generation Proteasome Inhibitors
155. Constitutive and immunoproteasome crystal structures reveal differences in substrate and inhibitor specificity
156. Targeting the immunoproteasome with the second generation proteasome inhibitor ONX 0914: effects on IFN-alpha-induced monocyte-derived dendritic cells (119.4)
157. Abstract 2854: Targeting constitutive NF-kB activation through Bruton's tyrosine kinase (Btk) and the proteasome in mantle cell lymphoma
158. Abstract 4796: Carfilzomib and ONX 0912 reduce the level of STAT3 phosphorylation in human B-cell lymphoma cells in vitro and in vivo
159. Erratum: Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody‐secreting cells
160. Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
161. InactivatingPSMB5Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis
162. Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
163. The Antiviral Immune Response in Mice Devoid of Immunoproteasome Activity
164. Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects
165. Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients
166. Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,
167. Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression
168. Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
169. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
170. Abstract 2607: The benefits of irreversibility: Infusion administration of carfilzomib results in potent proteasome inhibition and improved safety in animals
171. Immunoproteasome activity controls the balance of inflammatory and regulatory gene expression in T helper cells (152.21)
172. Abstract 541: The oral proteasome inhibitor ONX 0912 has bone anabolic effects in addition to anti-myeloma effects
173. PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo
174. Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization
175. Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome
176. A Simple and Rapid Method for Selecting High Producers of Recombinant Proteins in Individual Clones of P. pastoris
177. Intrusion detection through knowledge sharing
178. Proteasomes in immune cells: more than peptide producers?
179. Abstract B104: The orally bioavailable proteasome inhibitor PR‐047 inhibits metastasis in a mouse mammary carcinoma model
180. Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.
181. Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.
182. Pharmacokinetics, Metabolism, Distribution and Excretion of Carfilzomib in Rats.
183. Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.
184. Erratum: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
185. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
186. Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
187. Regional right ventricular wall motion in tetralogy of fallot: a three dimensional analysis
188. Inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by flavonoids: A quantitative structure-activity relationship study
189. The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration
190. Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome
191. Endocrine disrupting alkylphenols: Structural requirements for their adverse effects on Ca2+pumps, Ca2+ homeostasis & Sertoli TM4 cell viability
192. An E. coli expression system optimized for DELLA proteins
193. Effects of Endocrine Disruptors on Dehydroepiandrosterone Sulfotransferase and Enzymes Involved in PAPS Synthesis: Genomic and Nongenomic Pathways
194. Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
195. Inositol Lipids and Phosphates in the Proliferation and Differentiation of Lymphocytes and Myeloid Cells
196. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
197. Expression in Escherichia coli and in vitro refolding of the plant transcription factor Arabidopsis thaliana RGL3
198. A novel peptide tag for detection and purification of recombinant expressed proteins
199. Ricolinostat ( ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
200. Metabolism, Disposition and Pharmacokinetics of PR-171, a Novel Inhibitor of the 20S Proteasome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.